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Summary 
Cellular oxidative stress results from the increased generation of reactive oxygen 
species (ROS) and/or the dysfunction of the antioxidant systems. Most intracellular 
ROS derive from superoxide radical although the majority of the biological effects of 
ROS are mediated by hydrogen peroxide. In this contribution we overview the major 
cellular sites of ROS production, with special emphasis in the mitochondrial pathways. 
ROS regulate signaling pathways involved in promoting survival and cell death, 
proliferation, metabolic regulation, the activation of the antioxidant response, the 
control of iron metabolism and Ca2+ signaling. The reversible oxidation of cysteines in 
ROS transducers is the primary mechanism of regulation of the activity of these 
proteins. Next, we present the mitochondrial H+-ATP synthase as a core hub in energy 
and cell death regulation, defining both the rate of energy metabolism and the ROS-
mediated cell death in response to chemotherapy. Two main mechanisms that affect the 
expression and activity of the H+-ATP synthase down-regulate oxidative 
phosphorylation in prevalent human carcinomas. In this context, we emphasize the 
prominent role played by the ATPase Inhibitory Factor 1 (IF1) in human carcinogenesis 
as an inhibitor of the H+-ATP synthase activity and a mediator of cell survival. IF1 
promotes metabolic rewiring to an enhanced aerobic glycolysis and the subsequent 
production of mitochondrial ROS. The generated ROS are able to reprogramme the 
nucleus to support tumor development by arresting cell death.  Overall, we discuss the 
cross-talk between ROS signaling and mitochondrial function that is crucial in 
determining the cellular fate. 
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List of abbreviations: AIF, apoptosis inducing factor; Akt, v-Akt murine thymoma 
viral oncogene; AP-1, activator protein 1; ARE, antioxidant responsive element; ASK1, 
apoptosis signal-regulated kinase 1; ATM, ataxia teleangiectasia mutated; Duox, Dual 
oxidase enzymes; DUSP3, dual-specific phosphatase 3; ETC, electron transport chain; 
GPXs, glutathione peroxidases; GSH, glutathione; GST, glutathione S-transferase; 
HIF1α, Hipoxia Inducible Factor 1; HO1, heme oxygenase-1; IER3, immediate early 
response gene; InsP3R, InsP3 receptor; IF1, ATPase Inhibitory Factor 1; IRE, iron-
responsible elements; IRP, iron regulatory protein; JNK1, c-Jun N-terminal kinase 1, 
monoamine oxidase (MAO); mROS, mitochondrial reactive oxygen species; NFkB, 
nuclear factor kappa-light-chain-enhacer; NOX, NADPH oxidase; Nrf2, NFE2-like 2; 
O2-, superoxide radical, .OH, hydroxyl radical; OONO, peroxynitrite; OXPHOS, 
oxidative phosphorylation, p66Shc, 66 kDa proto-oncogene; SERCA, sarco/endo-
plasmic reticulum Ca2+ -ATPase; Src homologous-collagen homologue (Shc) adaptor, 
PI3K, phosphoinositide-3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, 
phosphatidylinositol (3,4,5)-trisphosphate; PP2A, protein phosphatase 2A ; PRXs, 
peroxiredoxins; PTEN, phosphatase and tensin homolog; PTP, permeability transition 
pore; PTP1b, phosphotyrosine protein phosphatase; Ref-1, redox factor-1; RNS, 
reactive nitrogen species; ROS, reactive oxygen species; RyR, ryanodine receptor; 
SODs, superoxide dismutases; UTR, untranslated region; VHL, von Hippel-Lindau; 
Δψm, mitochondrial membrane potential. 
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1. Introduction 
Oxidative stress is a phenotypic trait of many tumors. Main causes of this 
phenotype are the increased generation of reactive oxygen species (ROS) and the 
dysfunction of the antioxidant systems in cancer cells. ROS generation and scavenging 
are tightly connected to the metabolic state of the cell and especially to the activity of 
mitochondria. Nowadays, it is accepted that the roles played by cellular ROS are highly 
dependent on the level at which they are being produced. In this regard, it has been 
reported that high levels of ROS lead to increased cell death inhibiting tumorigenesis 
and metastasis [1], whereas low levels of ROS have an effect in promoting 
tumorigenesis by activating the signaling pathways that regulate proliferation, 
angiogenesis and metastasis [2, 3], stressing the relevance of ROS as important 
signaling molecules that regulate cell fate. In this review we will briefly summarize: (i) 
the sites of production, mechanism of action and signaling pathways that are activated 
by ROS and (ii) the role of the mitochondrial H+-ATP synthase in ROS-signaling cell 
death or cell survival paying, in the latter case, especial attention to the new 
physiological function unveiled for the ATPase Inhibitory Factor 1 (IF1) as a main 
regulator of the oncogenic phenotype in some prevalent carcinomas.  
2. ROS dynamics and signaling. 
2.1. Major cellular sites of ROS production.  
Most intracellular ROS are derived from the superoxide radical (O2-), which is 
the product of the one electron reduction of O2 (Fig. 1). Superoxide is then converted to 
hydrogen peroxide (H2O2) by superoxide dismutases (SOD1, SOD2 and SOD3) (Fig. 
1). The enzymes peroxiredoxins (PRXs), glutathione peroxidases (GPXs) and catalase 
are responsible for removing cellular H2O2 (Fig. 1), a process that is tightly regulated 
[4]. H2O2 can also react with iron to generate hydroxyl radicals (.OH) that are main 
drivers of the modifications in proteins, lipids and DNA that result in oxidative stress 
(Fig. 1).  
Several enzymes produce superoxide radical in the cell. Among them, NADPH 
oxidase is the best described enzymatic source of superoxide that uses NADPH as an 
electron donor (Fig. 1) [5, 6]. NADPH oxidases include the Nox family members 
(Nox1-5) and the Dual oxidase enzymes (Duox1-2) that are expressed in numerous 
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tissues [6-8]. These enzymes play important roles in cell signaling, regulation of gene 
expression, cell death, differentiation and growth [9]. Nox enzymes have developed 
different regulatory mechanisms depending of their function [6, 8, 10-12]. ROS 
produced by Nox proteins can act both intra- and extra-cellularly. These enzymes 
generate superoxide at the plasma membrane, in endosomes and in the endoplasmic 
reticulum [13, 14]. ROS produced by Nox2 have a main physiological role in the 
respiratory burst that occurs in phagocytes. Nox1 in the colon and Duox1 and 2 in the 
lung also play important roles in host defense [15]. However, ROS derived from Nox 
also participate in signaling as they can specifically and reversibly alter the activity, 
localization and half-life of proteins in response to various stimuli [9]. The 
phosphoinositide-3-kinase (PI3K) [16] and nuclear factor kappa-light-chain-enhancer of 
activated cells (NFkB) [13] pathways are two important signaling routes in which 
NADPH oxidases are involved. Fibroblasts over-expressing Nox1 displayed increased 
levels of superoxide and exhibited a transformed phenotype [17]. Moreover, it has been 
described that Nox1 signals angiogenic and tumorigenic effects through hydrogen 
peroxide [18]. Excess ROS produced by Nox5 have also been related to cancer [19, 20]. 
A substantial portion of cellular ROS is generated in mitochondria. There are 
eight sites in mitochondria that have the ability to produce ROS [21]. The mitochondrial 
electron transport chain (ETC) is the major site of non-enzymatic formation of 
superoxide radical (Fig. 2). The ETC is composed of four multiprotein complexes (I-IV) 
located in the inner mitochondrial membrane. Complexes I, II and III have the ability to 
produce superoxide as a result of the flux of electrons through the ETC. Complexes I, II 
and III produce ROS within the mitochondrial matrix whereas complex III also 
generates ROS and releases it into the intermembrane space (Fig. 2) [22]. Importantly, 
ROS generated in the intermembrane space are supposed to access the cytosol in a faster 
way what may confer them signaling advantages [3, 23]. ROS are released to the 
cytosol through voltage-dependent channels that are constituents of the permeability 
transition pore (PTP) and by the inner membrane anion channel (IMAC) [24, 25]. The 
transition of ROS from mitochondria to the cytosol is crucial in the regulation of 
programmed cell death geared by mitochondria [25, 26]. 
Other important sources of mitochondrial ROS (mROS) are p66Shc and 
monoamine oxidase (MAO) (Fig. 2). The protein p66Shc plays key roles in the 
oxidative stress response by inducing apoptosis under stressful conditions (Fig. 2) [27]. 
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p66Shc acts as a redox protein due to its capability to interact and oxidize cytochrome c 
(Fig. 2) [28]. MAO is a flavoenzyme bound to the outer mitochondrial membrane that 
catalyzes the oxidative deamination of neurotransmitters and monoamines. MAO 
represents a significant source of ROS production in brain mitochondria where it has 
been shown to generate ROS in a much higher amount than the respiratory chain [29]. 
In fact, MAO is involved in multiple neuropathologies and myocardial diseases and its 
inhibition is likely to provide a promising target for the relief of the oxidative stress that 
is associated with these pathologies [30]. 
The overproduction of ROS in response to metabolic stress triggered by hypoxia 
or chemotherapy promotes an oxidative stress that has been invariably linked to 
multiple pathologies including neurodegenerative diseases, diabetes, cancer and 
premature aging [3]. Nowadays, it is indubitable that mROS are important signaling 
intermediates in the communication of the organelle with other compartments and 
cellular processes for maintenance of homeostasis under different conditions and for 
adaptation to stress [3]. In fact, mROS can balance between survival and cell death in a 
process that is highly dependent on the levels at which they are being produced [31]. 
For instance, the mitochondrial release of H2O2 in hypoxia activates the transcription 
factor hypoxia inducible factor 1 (HIF1α), which is required for metabolic adaptation 
under low oxygen tension [32, 33]. In addition, the mitochondrial release of H2O2 has 
been reported to activate key signaling proteins such as c-Jun N-terminal kinase 1 
(JNK1), p53 and NFkB [34-36]. Numerous reports highlighting the importance of 
mROS-dependent signaling in a variety of systems and processes have emerged in the 
literature of the last decade [3, 31, 37-39]. 
It is well established that mROS production is highly dependent on the proton motive 
force as has been shown by titration of the mitochondrial membrane potential (Δψm) 
with uncouplers [40-42]. Perhaps, the best characterized site of ROS production in 
mitochondria is at complex III of the ETC (Fig. 2) [43]. The production of superoxide 
during forward electron transfer at complex III is low but significantly increases by 
reverse electron flow under conditions of hypoxia [44] or cellular toxicity [40, 42] from 
substrates that feed electrons to complex II. The fact that mitochondria produce more 
ROS under low oxygen levels is intriguing because it seems to contradict the 
dependence of mROS formation on the availability of oxygen that was observed in 
isolated mitochondria [43, 45]. It is likely that mROS generated in cells in response to 
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hypoxia depend on additional factors of the hypoxic cellular environment by 
mechanisms that remain to be elucidated (see [43] for details). In general, cellular 
conditions that slow-down the rate of electron transfer to molecular oxygen in the 
respiratory chain (Fig. 2) at high values of Δψm favor the generation of superoxide 
radical in mitochondria. One such situation is provided by inhibition of the back-flow of 
H+ through the H+-ATP synthase (Fig. 2) that is mediated by the over-expression of IF1 
in human carcinomas [38, 46-48] (see following section). In this situation, Δψm 
provides a link between energy metabolism, ROS production and cell fate [47]. 
2.2. Cysteine oxidations regulate the activity of ROS transducers.  
The regulation of signaling pathways by ROS is exerted by their ability to 
promote reversible posttranslational modifications of proteins [42, 49, 50]. Hydrogen 
peroxide is more stable than superoxide radical and is also capable of crossing 
biological membranes so the protein modifications mediated by ROS are predominantly 
H2O2-dependent. However, superoxide itself has been shown to be involved in aging 
related processes [51]. H2O2 can reversibly oxidize thiol groups (-SH) of redox-reactive 
cysteine (Cys) residues on proteins to form disulfide bonds (-S-S-) or sulfenic acid 
(−SOH), the latter can be further oxidize to sulfinic (−SO2H) and sulfonic (−SO3H) acid 
(Fig. 3) [31, 52]. Sulphenic acid (-SOH) can react with glutathione (GSH) to become 
glutathionylated (-SSG) (Fig. 3). These oxidative modifications result in changes in the 
structure of the targeted proteins thereby affecting its activity in the signaling pathways 
in which they are involved. In addition, the generation of intermolecular disulfide bonds 
can promote the homo- and/or heterodimerization of proteins that lead to the activation 
or repression of the signal transducers. Thiol groups can also react with reactive 
nitrogen species (RNS) forming S-nitrosothiol groups (-SNO) (Fig. 3). With the 
exception of sulfonic and sulfinic acid that are essentially irreversible reactions the 
modification of cysteines is reversible by the action of the reducing systems of the cell 
such as glutathione, thioredoxin and peroxiredoxin (Fig. 3) that are critical elements in 
redox sensing and signaling (Fig. 3) [53-55]. Phosphatases such as phosphotyrosine 
protein phosphatase (PTP1b), phosphatase and tensin homolog deleted on chromosome 
ten (PTEN) and MAPK phophatase are known examples of proteins involved in 
signaling pathways inactivated by H2O2 oxidation of cysteines [56, 57]. Superoxide also 
reacts with nitric oxide (NO), forming highly reactive and potentially damaging 
peroxynitrite (OONO−) [58]. The formation of peroxynitrite from O2- can lead to 
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reversible glutathionylation of proteins on reactive cysteines, as has been reported for 
the Na+-K+ ATPase [59]. The inactivation of aconitase by reaction of superoxide with 
(FeS)4 clusters provides an example of the inhibition of the activity of a metabolic 
enzyme mediated by the interaction of O2- and iron [60, 61].  
2.3. Overview of signaling pathways regulated by ROS.  
Low or transient ROS levels can activate kinases and/or inhibit phosphatases 
involved in a wide variety of cell signaling processes by oxidizing critical cysteine 
residues of the proteins (Fig. 4) [62, 63]. Proteinases and matrix metalloproteins have 
also been described as ROS targets [64]. Thioredoxin that catalyzes the reversible 
reduction of disulfides to a dithiol in ROS targeted proteins (Fig. 3) interacts in its 
reduced state with apoptosis signal-regulated kinase 1 (ASK1) that is activated under 
oxidative stress (Fig. 4) [65]. Thioredoxin-ASK1 interaction blocks oligomerization of 
ASK1 and its subsequent activation [66, 67].  When thioredoxin is oxidized by ROS, it 
disassociates from ASK1 allowing protein oligomerization and subsequent activation 
through auto-phosphorylation [68]. This kinase mediates apoptosis by regulating the 
JNK and p38 MAPK pathways [69]. The regulation of differentiation [70] and immune 
signaling [71] mediated by ASK1 through the p38 MAPK pathway are other important 
biological effects triggered by ROS. Importantly, thioredoxin is also involved in the 
regulation of AMPK activity by preventing the oxidation of cysteine residues in the α 
subunit of the metabolic stress kinase [72].  This elegant study links oxidative stress and 
metabolism demonstrating that a reducing enzyme is a critical cofactor controlling the 
activation of AMPK, a key regulator of metabolism and cell survival in situations of 
energy stress [72] (Fig. 4).   
The best-characterized example of ROS-mediated inactivation of phosphatases 
by the oxidation of the active site cysteine residue of the enzyme is that of protein 
tyrosine phosphatase 1b (PTP1b). The inactivation of this enzyme results in the 
promotion of MAPK and growth factor signaling pathways initiated from different 
stimulus (Fig. 4) [62, 73-76]. Additionally, ROS can inactivate the dual-specific 
phosphatase 3 (DUSP3) that is another protein tyrosine phosphatase involved in the 
dephosphorylation of ERK1/2 causing the sustained activation of the ERK1/2 signaling 
pathway [77] that play an essential role in cell proliferation, differentiation, invasion, 
and apoptosis [78-80].  
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The PI3K pathway which is important for cellular growth, survival and 
proliferation (Fig. 4) [81] can be affected by the redox state of the cell through different 
mechanisms [82]. For example, Akt that is a main protein kinase downstream in the 
pathway has been shown to be activated by H2O2 [83]. The target of ROS in the PI3K 
pathway is the tumor suppressor PTEN, a phospholipid phosphatase that converts PIP3 
back to PIP2 thus acting as a negative regulator of the pathway [82, 84]. PTEN is 
inhibited by hydrogen peroxide through disulfide bond formation between the active 
site cysteine (Cys124) and a vicinal cysteine residue [85-87]. Through PTEN, the PI3K 
pathway is subject to reversible redox regulation by ROS generated by growth factor 
stimulation [88]. PTEN oxidation is reversed by cytoplasmic peroxiredoxin II that 
eliminates the H2O2 generated in response to growth factors [85]. Mitochondrial-
generated ROS can also inhibit PTEN affecting the angiogenesis process [89]. Protein 
phosphatase 2A (PP2A) which is involved in the dephosphorylation of Akt [90] and the 
inactivation of the PI3K/Akt pathway [91] is another redox sensitive phosphatase.  By 
inhibiting these important phosphatases the AKT signaling pathway is deregulated 
promoting uncontrolled cellular proliferation and enhanced survival and growth. Ataxia-
teleangiectasia mutated (ATM) protein (Fig. 4) is a  PI3K-like serine/threonine protein 
kinase that is activated under stressful conditions and phosphorylates various proteins 
involved in cellular proliferation, death, survival and DNA repair [92, 93]. ATM is 
preferentially activated by DNA double strand breaks and also acts as a sensor of 
oxidative stress [94]. ATM protein is also regulated by a redox sensitive mechanism via 
the formation of active ATM dimers through intermolecular disulfide bond formation 
(Fig. 3) [95].  
The hypoxia inducible transcription factor HIF1α is also a target of ROS (Fig. 4) 
[23]. HIF1α is responsible for the coordination of the cellular responses to decreased 
oxygen availability [96, 97]. During normoxia prolyl hydroxylation of HIF1α promotes 
its association with the von Hippel-Lindau (VHL) tumor suppressor that targets the 
protein for ubiquitination and degradation. However, during hypoxia the hydroxylation 
of proline in HIF1α is inhibited due to the inactivation of prolyl hydroxylases.  mROS 
are involved in the stabilization of HIF1α to promote the transcriptional activity of the 
protein [32, 98-101]. The stabilization of HIF1α under low oxygen conditions requires 
the generation of ROS in complex III of the ETC [102]. In other words, the 
mitochondrial respiratory chain acts as an O2 sensor that activates a signaling cascade to 
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stabilize HIF1α through the production of ROS. First evidences illustrating that mROS 
are involved in the regulation of HIF1α aroused from studies in cells depleted of 
mitochondrial DNA (ρo cells) that failed to stabilize HIF1α under hypoxia [32]. HIF1α 
stabilization is blunted by treating the cells with mitochondrial antioxidants 
emphasizing that mitochondria are the source of ROS under hypoxic conditions [32, 
33]. Moreover, inhibitors of the mitochondrial electron transport chain that block HIF1α 
activation in hypoxia have also been described [103]. The mROS mediated regulation of 
HIF1α is implicated in regulating tumorigenesis by controlling genes involved in 
metabolism, angiogenesis, and metastasis [97, 104].  
As discussed previously mROS produced in p66Shc play relevant roles in the 
activation of the apoptotic pathway and in the regulation of life span [27]. The 
production of mROS by this protein leads to mitochondrial damage and apoptosis under 
oxidative or genotoxic stress conditions [105]. The mechanisms that mediate 
mitochondrial translocation of p66Shc and its proapoptotic activity seem to be 
controlled by protein phosphorylation [106], although it has also been suggested that 
ROS production and the initiation of apoptosis by p66Shc is also redox sensitive by 
formation of two disulfide bonds in the protein (Fig. 4) [107]. The interaction observed 
between p66Shc with the TOM-TIM protein import complexes [105, 108] and with 
cytochrome c [28] are also mechanisms involved in the proapoptotic function of the 
protein (Fig. 2).  
An important point in the cellular response to increased levels of ROS is the 
redox regulation of transcription factors that activate the antioxidant defense system 
(Fig. 4). The transcription factor redox factor-1 (Ref-1) is a multifunctional protein that 
translocates to the nucleus upon exposure to genotoxic agents and H2O2 and initiates a 
protective response of the cell from DNA and oxidative damage [109, 110]. Ref-1 
regulates the transcriptional activity of several key transcription factors involved in 
cellular defense such as activator protein 1 (AP-1), p53, NFkB and HIF1α by its redox 
sensitive cysteine residues [111-113].  The antioxidant genes glutathione S-transferase 
(GST) [114], NADPH quinone oxidoreductase-1 (NQO1) [115] and heme oxygenase-1 
(HO1) [116, 117] are regulated by an enhancer termed the antioxidant responsive 
element (ARE) [118]. H2O2 activates transcription of these genes via the ARE element 
and involves a complex set of redox regulated proteins [119]. The primary transcription 
factor involved in ARE activation is the redox-sensitive transcription factor NFE2-like 2 
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(Nrf2) [120] (Fig. 4) that is translocated into the nucleus under oxidative stress [121]. In 
the nucleus Nrf2 dimerizes with the small Maf proteins and binds the ARE to activate 
ARE-dependent transcription of target genes in ROS homeostasis [118, 122]. 
Interestingly, the transcriptional activity of Nrf2 is also regulated by Ref-1 [123] 
indicating the collaboration of these proteins in the detoxification of the cell under 
oxidative stress. 
Extensive literature has related ROS and Ca2+ signaling and their effects on 
apoptosis, aging and cardiovascular diseases [124] (Fig. 4). ROS can modify the 
properties and activities of some of Ca2+ channels and transporters [125, 126]. In fact, 
some of the proteins involved in Ca2+ signaling such as the InsP3 receptor (InsP3R) 
[127], the ryanodine receptor (RyR) channels  [128] and the sarco/endo-plasmic 
reticulum Ca2+-ATPase (SERCA) [129] have been shown to be sensitive to ROS.  
In addition, ROS signaling is also important for the maintenance of iron 
homeostasis (Fig. 4). Iron is an essential element that plays crucial roles in cell 
proliferation and metabolism as it represents a functional constituent of various 
enzymes. Excessive levels of free iron can generate ROS via the Fenton reaction [130, 
131] promoting deleterious oxidative stress to the cells (Fig. 1). Iron regulatory protein-
1 and -2 (IRP1 and IRP2) regulate the expression of many genes involved in iron 
transport and storage at the posttranscriptional level by interacting with iron-responsive 
elements (IRE) in the 5′- or 3′-untranslated region (UTR) of the mRNAs. IRP1 and 
IRP2 have redox sensitive target sites that are subjected to redox regulation by H2O2 
and nitric oxide [132-135]. Taken together, the IRE–IRP regulatory system is also 
regulated by ROS to elicit a defense mechanism against iron-catalyzed oxidative stress. 
 
3. Old and new functions of the H+-ATP synthase. 
3.1. The H+-ATP synthase, a core hub in energy and cell death regulation.  
The oxidation of glucose in the cytoplasm and the subsequent oxidation of 
pyruvate in mitochondria provide the energy, reducing power and carbon skeletons 
required for the maintenance of cellular homeostasis and proliferation [47, 136]. 
Normoxic cells oxidize most of the pyruvate to CO2 in mitochondria and the electrons 
collected onto NADH and FADH2 are transferred to the complexes of the respiratory 
chain to generate the proton electrochemical gradient that is used for the synthesis of 
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ATP in oxidative phosphorylation (OXPHOS) (Fig. 2). ATP is synthesized by the 
mitochondrial H+-ATP synthase, a reversible engine of the inner mitochondrial 
membrane that provides most of the ATP that is required to maintain cellular activities 
in normal aerobic differentiated cells [47]. The mammalian H+-ATP synthase consists 
of two main domains: a membrane-bound hydrophobic FO portion, which contains the 
proton channel, and the soluble catalytic F1 portion that encloses the adenine nucleotide 
binding sites at the α/β subunit interface [137, 138]. Both regions are linked together by 
a central and a peripheral stalk. In normal aerobic cells under phosphorylating 
conditions, the re-entrance of protons into the mitochondrial matrix (Fig. 2) triggers the 
rotation of the c-ring in FO and of the attached central stalk to induce the 
conformational changes in the β-F1-ATPase subunit that drive the synthesis of ATP 
(Fig. 2).  
 The cellular availability of ATP, NADH and some metabolic intermediates 
coordinate at short-term the flux of glucose consumption by regulating the activity of 
key enzymes of the glycolytic pathway and mitochondrial dehydrogenases, to limit the 
production of biological energy as it is being demanded [47]. In other words, the 
efficient production of biological energy by OXPHOS determines the rate of glucose 
consumption, which is nowadays formulation of the Pasteur Effect [139]. When the 
cells have a limited supply of oxygen or have a genetic or epigenetic impairment that 
restrains OXPHOS, glycolysis is enhanced [47, 140]. When short-term regulation of 
enzyme activities of energy metabolism is not enough to cope with the energetic 
demand cells onset the gene expression programs required for adaptation. Examples that 
are relevant in this regard are the induction of glycolysis during adaptation to hypoxia 
[141], the rewiring of metabolism in cancer [142] and in dedifferentiation of somatic 
cells [143], the onset of the bioenergetic function of mitochondria during adaptation of 
mammals to the aerobic extrauterine environment [144, 145] and the metabolic 
reprogramming that accompanies stem cell differentiation [146, 147]. 
3.2. The H+-ATP synthase in signaling cell death.  
Down-regulation of oxidative phosphorylation (OXPHOS) and the concurrent 
activation of aerobic glycolysis is a hallmark of proliferating cancer cells [140, 148]. 
Whereas the increase of glycolysis in the majority of carcinomas is nowadays out of 
question, the role of OXPHOS modifications in tumor development and progression is 
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still debated [47]. Nevertheless, it has been shown that a dysfunctional OXPHOS 
promotes cellular proliferation and invasion [47, 149] whereas an increase in oxidative 
metabolism halts cellular proliferation and tumor progression [47, 140, 150, 151]. In 
this regard, the activity of OXPHOS has been demonstrated to be specifically required 
for the execution of cell death [47, 152-154]. In particular, molecular components that 
participate in OXPHOS, such as cyt c, AIF and subunits of the H+-ATP synthase are 
needed for the execution of cell death [40, 155-158]. Hence, bioenergetics and cell 
death are two master tasks of mitochondria that are molecularly and functionally 
integrated [47].  
The impairment of mitochondrial energy production by metabolic stress and/or 
in response to chemotherapy leads to increased ROS generation through respiratory 
chain electron leakage. ROS can signal mitochondrial geared cell-death pathways or 
activate transcription programs aimed at cell survival, two opposite cellular fates that 
largely depend on the intensity of the ROS signal [1, 31]. The induction of cell death by 
different stressful conditions promotes Δψm collapse that is preceded by transient 
mitochondrial hyperpolarization [40, 156, 159] and the subsequent production of mROS 
which is highly dependent on Δψm [40, 42, 160]. It has been suggested that mROS 
produced in response to cell death stimulation occurs by reverse electron flow from 
complex II-linked respiratory substrates into complex I of the ETC (Fig. 2) because its 
production can be inhibited with rotenone [40, 42, 161]. Consistent with a role for 
mROS in the execution of cell death [1, 162], extensive protein carbonylation of cellular 
proteins as well as covalent modifications in mitochondrial proteins have been reported 
in response to staurosporine treatment [40]. The generation of mROS preceded the 
release of cyt c, the activation of caspase 3 and cell death [40]. Upon inhibition of 
mitochondrial respiration with staurosporine [163] it is suggested that the hydrolysis of 
glycolytic ATP by reverse functioning of the H+-ATP synthase maintains Δψm [40, 
164-166]. In this situation, the inhibition of the activity of the H+-ATP synthase with 
oligomycin blunted mitochondrial hyperpolarization and ROS production, prevented the 
oxidation and modification of mitochondrial proteins, delayed the release of cyt c and 
the execution of cell death [40, 164].  
In contrast to these findings, the 1,4-benzodiazepine-derivative Bz-423 signals 
apoptosis by the induction of ROS production from the mitochondrial respiratory chain 
as a result of the inhibition of the H+-ATP synthase [167]. The antagonistic effects on 
  14
apoptosis of oligomycin and Bz-423 seem to be dependent on the different mechanism 
by which these compounds inhibit the enzyme [167]. Similarly, the drug 3,3`-
diindolylmethane also promotes ROS-mediated cell death by inhibiting the H+-ATP 
synthase [168]. In any case, these findings support a role for the activity of the H+-ATP 
synthase in controlling the extent of oxidative damage to mitochondrial constituents that 
will effectively swamp the cells into death [40]. Consistently, the cell death response to 
different chemotherapeutic agents varies largely depending upon the relative activity of 
the pathways that sustain energy metabolism (Fig. 5) [40, 169]. In fact, highly 
glycolytic cells with negligible contribution of OXPHOS for ATP provision have a cell-
death resistant phenotype because mROS signaling after chemotherapeutic targeting is 
blunted (Fig. 5) [40, 169]. Overall, the down-regulation of the H+-ATP synthase, and 
thus of OXPHOS, is part of the molecular strategy adapted by cancer cells to avoid 
reactive oxygen species-mediated cell death.  
Interestingly, it has been shown that the activity of the H+-ATP synthase per se 
is inhibited by ROS [170, 171]. The impact of ROS on the activity of the complex is 
also observed in chloroplasts where the γ subunit seems to be a main target for ROS 
oxidation [172]. These findings further emphasize the tightly regulated connections that 
exist between the H+-ATP synthase, energy production, ROS generation and cell death.  
The point of no return in cell death is the permeabilization of the inner 
mitochondrial membrane to low molecular weight solutes, the so-called PTP opening 
[173-175]. Although the molecular composition of the PTP remains unknown recent 
findings support that a critical component of the high-conductance channel is subunit c 
of the H+-ATP synthase [176]. Moreover, it has been shown that dimers of the H+-ATP 
synthase form a channel with electrophysiological properties identical to those of the 
PTP [177]. Non-specific ROS-mediated modifications of mitochondrial constituents 
could represent a critical point of regulation of the mitochondria-geared cell death 
pathway. Protein oxidation could define the threshold value of irreversible damage of 
the mitochondria and the set-point for the release of the mitochondrial arsenal that 
controls cell death (Fig. 5) [40]. Indeed, oxidative stress promotes cell death by 
increasing the susceptibility of the opening of the PTP [178]. PTP opening is linked to 
oxidative stress since it has been shown to be dependent on the NADPH redox state 
[179, 180] and promoted by thiol oxidation [181, 182]. Consistently, it has been 
reported that PTP opening can be stimulated by the addition of exogenous sources of 
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ROS and prevented by antioxidants in pro-apoptotic conditions [180]. Interestingly, 
PTP opening also increases mitochondrial ROS production illustrating a retro-
amplification cascade when the decision to execute cell-death has been taken [183].  
Consistent with the tumor suppressor function of mitochondrial activity there is 
a large body of data supporting that OXPHOS, both under basal conditions or in 
response to chemotherapeutic agents abolishes tumorigenicity (see [47] for updated 
review). A likely mechanism that explains the preferential death of cancer cells when 
forced to oxidize mitochondrial substrates is the overproduction of superoxide radical as 
a result of the stimulation of mitochondrial metabolism [40, 47, 184]. Both genetic 
[185] and pharmacological [186] studies have shown that the PGC1α-mediated 
improvement of mitochondrial activity and metabolism restrains cancer progression by 
increasing ROS-mediated apoptosis in cancer cells [185].  
A diverse set of genetic, epigenetic and environmental mediated mechanisms 
interfere with mitochondrial bioenergetics of the cancer cell [47, 187]. One such 
mechanism, which is observed in many prevalent human carcinomas, is the down-
regulation of the expression of the catalytic subunit of the mitochondrial H+-ATP 
synthase (β-F1-ATPase) relative to the enzyme of glycolysis glyceraldehyde-3-
phosphate dehydrogenase [140, 188]. This finding has been confirmed and extended to 
other carcinomas (see [140] for other studies), providing a “bioenergetic signature” of 
cancer [140, 188] of clinical applicability. Indeed, as assessed in large cohorts of colon 
[188-190], lung [191, 192], breast [193] and ovarian carcinomas [194] and in cells of 
acute myeloid leukemia patients [195] the altered bioenergetic signature of the tumors 
predicts a worst overall and/or disease-free survival for the patients. Down-regulation of 
the bioenergetic signature is also functionally linked to the resistance to chemotherapy 
in many different cancer cells [47, 196, 197], in colon cancer patients [190] and chronic 
[198] and acute [195] leukemia patients. In general, the bioenergetic signature 
represents a functional index of metabolic activity of the cells because it correlates, both 
in vitro [199] and in vivo [192], with the rate of glucose utilization. Overall, these 
findings emphasize that a diminished bioenergetic activity of mitochondria in the cancer 
cell predisposes to cancer onset and progression, highlighting the emerging role that the 
H+-ATP synthase plays as a master regulator of cell death [40, 156, 177, 200, 201]. 
Consistently, cancer progression requires the silencing of the bioenergetic activity of 
mitochondria [199] not only by down-regulating the content of the H+-ATP synthase as 
  16
above discussed but also by over-expressing the natural physiological inhibitor of the 
enzyme, the so-called ATPase Inhibitory Factor 1 (IF1) [38, 46, 47].   
3.3. The ATPase Inhibitory Factor 1 (IF1).  
In mitochondria, ATP hydrolysis by the H+-ATP synthase is inhibited by the 
ATPase Inhibitory Factor 1 (IF1) that reversibly binds to the enzyme (Fig. 6) [202, 
203]. The natural inhibitor of the H+-ATP synthase is a low molecular weight (~10kDa) 
mitochondrial protein which inhibited the soluble ATPase, but did not interfere with its 
coupling activity [204]. IF1 is encoded in the nuclear ATPIF1 gene located on 
chromosomes 1 and 4 in human and mouse, respectively. IF1 has been described in 
mammals, birds, amphibious, nematodes, yeast and plants and shows considerable 
sequence identity among various eukaryotes [205]. It is absent in bacteria and 
chloroplasts. Three different isoforms of the human protein are produced by alternative 
splicing.  Isoform 1 is the longest one, it codifies for a protein of 106 amino acids (12,2 
kDa; pI=10) which is, by far, the protein more abundantly expressed in most human 
tissues [46, 47]. Isoform 2 and 3 codify for proteins of 71 (7,9 kDa; pI=8.5) and 60 (6,6 
kDa; pI=9.3) amino acids, respectively. The inhibitor protein has an N-terminal 
presequence of 25 residues for targeting the protein into the mitochondrial matrix which 
is cleaved off after import [206, 207]. 
The interaction between IF1 and the H+-ATP synthase depends on the pH of the 
mitochondrial matrix and is affected by changes in the Δψm [202, 207]. IF1 binds β, α 
and γ subunits of the H+-ATP synthase due to its activation under low pH conditions 
blocking ATP hydrolysis and preventing a useless waste of energy [207]. The 
substitution of histidine 49 in the IF1 sequence by a lysine renders a mutant form of IF1 
(H49K) that is as active as IF1 in the inhibition of the ATP hydrolase activity but less 
sensitive to the regulation by pH [138, 202, 203, 208, 209]. The participation of E26 in 
the pH regulated inhibitory activity of bovine IF1 has also been suggested [210]. Bovine 
IF1 has been shown to have oligomeric states, tetramer and dimer, favored by pH values 
above and below 6.7, respectively [202]. Dimerization and activation of IF1 occurs by 
formation of an antiparallel α-helical coiled-coil in its C-terminal region which places 
the N-terminus (inhibitory regions) of the monomers at opposite ends of the dimer, 
allowing the dimeric IF1 to bind two domains of F1-ATPase simultaneously [202]. The 
structure of the inhibited F1-ATPase complex with bound IF1 in the presence of ATP 
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has been solved and confirms that the N-terminal region of the dimeric inhibitor is 
bound to F1-ATPase [138]. The inhibitory 42L-58K segment of IF1 has been shown to 
interact with α/β pair of subunits of the F1-ATPase domain. It is suggested that this 
interaction inhibits the conformational inter-conversions of the catalytic sites involved 
in ATP hydrolysis and hence rotatory catalysis [138]. Hence, the mechanism of 
inhibition of the ATPase by IF1 arises from the disruption of the catalytic site.  
The physiological function ascribed to IF1 in normal hypoxic cells is to inhibit 
the hydrolase activity of the H+-ATP synthase [202, 203, 211, 212]. Until recently, the 
role of IF1 in preserving cellular ATP in myocardial ischemia [209, 211] and in 
ischemic preconditioning [209] have been the most extensively studied functions of IF1. 
However, the transformation of mitochondria from ATP producers into ATP consumers 
under depolarizing conditions has been recently questioned [213]. Upon mitochondrial 
depolarization IF1 has been identified as an essential gene to promote PARK2 
recruitment onto mitochondria to establish the selective autophagic program of 
mitophagy [214]. More recent findings support a relevant role for IF1 in controlling the 
ferrochelatase activity of mitochondria, and hence heme biosynthesis, in erythroid cells 
[215].  Surprisingly, a recently ill-defined knockout IF1 mouse model has revealed no 
alterations in phenotype [216]. The absence of IF1 is known to occur in Luft’s disease, a 
mitochondrial myopathy of the striated muscle [209, 217, 218]. The disorder is 
characterized by a hypermetabolic state, mitochondria with densely packed cristae and a 
loosely coupled OXPHOS [209, 217, 219], suggesting additional functional roles for 
IF1 in the regulation of the H+-ATP synthase of muscle mitochondria. It has been 
shown that long rows of dimers of the H+-ATP synthase promote the high local 
curvature of the inner membrane at cristae ridges [220-223]. Interestingly, ageing seems 
to melt-down the inner-membrane cristae of mitochondria by age-dependent 
dissociation of ATP synthase dimers [224]. It has been suggested that IF1 regulates the 
oligomeric state of the H+-ATP synthase increasing the density of cristae and the 
formation of dimeric ATP synthase complexes [212, 225-227]. However, this 
suggestion has been questioned [228-230].  
3.4. IF1 is a master regulator of energy metabolism in cancer and in stem cells.  
A differential expression level of IF1 has been reported between different mouse 
[231] and human tissues [46, 48]. Moreover, cardiomyocytes of low heart rate species 
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(human) have a higher expression level of IF1 than cardiomyocites of fast heart rate 
species (rat, mouse) [209, 211], what might explain the differential preservation of 
cellular ATP upon sublethal ischemic episodes. Interestingly, normal colon, lung and 
breast tissue have negligible expression of IF1 [38, 46, 48]. In contrast, mitochondria of 
almost all lung, colon, breast and ovarian carcinomas analyzed in large cohorts of 
cancer patients show an overwhelming increase in the expression of IF1 [48]. We have 
demonstrated that the over-expression of IF1 results in the inhibition of the ATP 
synthetic activity of the H+-ATP synthase and the switch of the cells to an enhanced 
aerobic glycolysis [38, 46]. On the contrary, silencing of IF1 enhances the H+-ATP 
synthase activity and reduces aerobic glycolysis, strongly supporting a crucial role for 
IF1 in mediating the metabolic switch experienced by cancer cells [38, 46]. Likewise, 
IF1 is present in human mesenchymal stem cells (hMSCs) as well as in stem cells of the 
prostate and in the Lieberkühn crypts of the colon [147]. Consistent with a master role 
for IF1 in the regulation of energy metabolism we have shown that the regulated 
degradation of IF1 triggers metabolic rewiring from aerobic glycolysis to a predominant 
OXPHOS in the differentiation process of hMSCs into osteocytes [147], once again 
stressing the biological relevance of this protein in regulating energy metabolism of 
proliferating cells. 
3.5. The role of IF1 in ROS signaling cell survival.  
The IF1-mediated inhibition of the H+-ATP synthase results in mitochondrial 
hyperpolarization and the subsequent production of superoxide radical in colon [38] and 
other cancer [48] cells (Fig. 6). Therefore, besides the role of IF1 in rewiring energy 
metabolism [46, 232], the over-expression of IF1 also triggers a retrograde ROS signal 
to the nucleus to establish the appropriate adaptive cellular program needed to support 
tumor development [38, 48]. IF1 mimics the inhibitory effect of oligomycin in 
reprogramming energy metabolism and in inhibiting apoptosis [40, 156]. Remarkably, it 
has been demonstrated that the ROS-mediated response in colon cancer cells in 
response to the over-expression of IF1 signals to the nucleus an NF-κB-dependent 
adaptation that includes enhanced proliferation, invasion and cell survival [38]. An IF1 
ROS-mediated resistance to cell death has also been demonstrated in other cancer cells 
[48]. The ROS-signaling pathways (Fig. 4) activated in response to IF1 over-expression 
that arrest cell death in many prevalent human cancer cells still remain to be 
investigated [48]. An alternative, not mutually exclusive mechanism of action of IF1 to 
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prevent cell death is that it might contribute to stabilize the oligomerisation state of the 
H+-ATP synthase to preserve mitochondrial cristae impeding in this way the release of 
cyt c [233]. In this regard, IF1 has been suggested to increase the density of 
mitochondrial cristae by the formation of dimeric ATP synthase complexes [212]. In 
this situation, IF1 would represent a negative regulator of PTP opening [177] 
contributing to the evasion of cell death. Consistently, recent findings in a conditional 
transgenic mouse expressing H49K (a gain-of-function mutant of human IF1) in 
neurons that also inhibits the H+-ATP synthase supports both a ROS-mediated 
metabolic and structural pathways to prevent neuronal cell death in vivo after an 
excitotoxic insult [234]. Overall, these findings strongly support that IF1 plays a master 
role in the regulation of energy metabolism and in retrograde communication to the 
nucleus other features of the oncogenic phenotype such as cell survival [47, 187].  
3.6. Regulation of IF1 activity and expression and other IF1 paradoxes.  
In silico analysis of the promoter region of the human ATPIF1 gene reveal the 
existence of potential cis-acting responsive elements for transcription factors involved 
in cancer. Data from high-throughput ChiP-sequencing confirmed the binding of several 
transcription factors involved in the regulation of cell cycle (NF-YB, NF-YA, Ini1), 
proliferation (c-FOS, Sp1, c-MYC) inflammation and cell death (NFκB, TAF1) in the 
proximal promoter region of the ATPIF1 gene. However, the regulation of IF1 
expression in human carcinomas is exerted at post-transcriptional levels [48]. In fact, 
IF1 has a very short half-life (~2h) in colon cancer cells [48] being degraded by a 
mitochondrial protease [147]. However, the mitochondrial protease involved in IF1 
degradation has not been identified despite our recent attempts using a large siRNA 
screen [147]. It has been suggested that the hypoxia regulated transcription factor HIF1α 
participates in controlling IF1 expression (Fig. 4) [235]. Moreover, it has been shown 
that the immediate early response gene (IER3) binds the C-terminus of IF1 to render the 
protein prone to proteolytic digestion in HeLa cells [236]. However, recent findings in 
different cancer cell lines seem to exclude the participation of HIF1α [48] and of IER3 
[48] in controlling IF1 expression in colon, lung and breast carcinomas.  
Paradoxically, tissues with very high activity of OXPHOS (liver, muscle, 
neurons) show a very high content of IF1 [38, 46, 48, 234], what would imply the 
partial IF1-mediated inhibition of the H+-ATP synthase in these tissues, which is 
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obviously not the case. As recently pointed out [48], these findings suggest that besides 
to the well characterized pH controlled binding of IF1 to β-F1-ATPase [202], an 
additional mechanism should regulate the biological activity of IF1 specially in tissues 
that naturally over-express the protein. It has been described that IF1, in addition to 
binding subunits of the H+-ATP synthase, also binds other membrane proteins of 
mitochondria in a pH and Δψm independent manner [237]. Specifically, it has been 
shown that the binding to one of these membrane proteins (~ 5-6 kDa) hampers the 
activity of IF1 as an inhibitor of the ATPase [237]. Hence, it is conceivable that tissues 
that normally over-express IF1 could also express a putative receptor that might act as a 
negative regulator of IF1 in order to counterbalance its inhibitory activity, contributing 
in this way to the fine-tuning of OXPHOS. Alternatively, tissue-specific post-
translational modifications of IF1 [238] could explain its activity on the H+-ATP 
synthase. The biological relevance of these modifications and the proteins and signals 
involved are unknown but they are likely to be relevant to understand IF1 expression 
and activity. 
Interestingly, the study of IF1 expression in tumors of large cohorts of breast and 
colon cancer patients support that it represents a marker of clinical outcome [48]. 
Surprisingly, colon and breast cancer patients with high tumor expression of IF1 have a 
better prognosis in terms of time of disease relapse [48] what suggests that cancer cells 
with a low expression of IF1 should be more likely to metastasize [48]. The molecular 
bases of this paradox are presently unknown.  
4. Final Remarks 
We have outlined the main pathways that lead to superoxide production in 
mitochondria, the primary mechanism by which ROS modulate the activity of proteins 
involved in signaling pathways and their biological consequences in the cell response. 
The mitochondrial H+-ATP synthase is presented as a key transducer in controlling 
energy metabolism, ROS-mediated cell death or the retrograde ROS response that 
allows the acquisition of an enhanced proliferation and the resistance to cell death, key 
features of the phenotype observed in carcinomas. ROS signaling by mitochondria is 
important in cancer onset and progression and it might represent the remnant 
mechanism that allowed the successful symbiosis of the two organisms that gave rise to 
the aerobic eukaryotic cell. A master regulator of mitochondrial ROS production with 
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clear effects in promoting the malignant phenotype of cancer cells is the ATPase 
Inhibitory Factor 1. Characterizing the regulation of its expression and/or activity are 
critical issues to understand the regulation of OXPHOS in different mammalian tissues 
and of many of the hallmarks of the cancer phenotype. The development of tissue 
specific mouse models with regulated expression of IF1 will contribute to portray its 
functional role in cellular physiology and pathophysiology. Overall, we can conclude 
that bioenergetics, ROS production and cell death are master tasks of mitochondria that 
are molecularly and functionally integrated. Unveiling the mechanisms that mediate 
these signaling networks will bring up new opportunities for cancer therapies. 
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Figure Legends.  
Fig. 1. The metabolism of oxygen. Superoxide is mainly produced by NADPH 
oxidases and by the mitochondrial respiratory chain.  Superoxide is converted to 
hydrogen peroxide (H2O2) by superoxide dismutases (SODs). H2O2 is converted to 
water (H2O) by glutathione peroxidases (GPX), peroxiredoxins (PRX) or catalase. H2O2 
is the main player in ROS cellular signaling because it can promote posttranslational 
modifications in proteins by thiol oxidation. The reaction of H2O2 with iron (Fe2+) 
generate hydroxyl radicals (.OH) that are responsible for lipid, protein and DNA 
damage, promoting oxidative stress. 
Fig. 2. Overview of mitochondrial ROS production. The scheme shows the relevant 
sites of ROS production by mitochondria. The transfer of electrons obtained by the 
oxidation of NADH and FADH2 to molecular oxygen by respiratory complexes in the 
inner mitochondrial membrane is depicted by continuous red lines. The formation of the 
proton gradient generated by respiration and its utilization for the synthesis of ATP by 
the H+-ATP synthase in oxidative phosphorylation is indicated.  Complexes I, II and III 
produce superoxide (discontinuous red lines, ROS) and release it in the matrix. 
Complex III also releases ROS into the intermembrane space.  The activity of the H+-
ATP synthase also modulates the levels of ROS produced by mitochondria. ROS are 
also generated by the redox protein p66Shc which interacts with TOM-TIM protein 
import complexes and with cytochrome c (cyt c). MAO, which is located in the outer 
mitochondrial membrane, represents an additional source of ROS in mitochondria. 
Fig. 3. Regulation of protein activity by ROS. Proteins are regulated by ROS through 
the oxidation of thiol groups (-SH) of redox-reactive cysteine residues. Oxidation of 
these residues by ROS can form reactive sulfenic acid (-SOH) that can undergo further 
oxidation to sulfonic (-SO3H) acid or form disulfide bonds with nearby cysteines (-SS-). 
These modifications lead to the inactivation of the proteins. Disulfide bonds can be 
reduced by thioredoxin (TRX) reductase that recovers the activity of the protein. 
Sulphenic acid (-SOH) can also react with glutathione (GSH) becoming 
glutathionylated (-SSG). Protein activity can be recovered by the action of glutaredoxin 
(GRX) that recognizes glutathionylated substrates and utilizes glutathione (GSH) for the 
reduction of the –SSG groups. Thiol groups can also react with reactive nitrogen species 
(RNS) to form S-nitrosothiol groups (-SNO) that also trigger protein inactivation.   
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Fig. 4. Signaling pathways regulated by ROS. ROS regulate several signaling 
pathways with key roles in cellular processes by affecting the activity of critical 
molecules. ROS can mediate survival, proliferation, metabolism and cell death by 
regulating the activity of proteins involved in MAPK pathways such as, ASK1, PTP1b, 
and DUSP3. Proteins participating in the PI3K pathway such as AKT, PTEN, PP2A and 
ATM are also direct targets of ROS. HIF1α, p66Shc and AMPK are also regulated by 
ROS. ROS modulate the antioxidant response through the action of REF1 and NRF2. 
The iron regulatory proteins IRP1 and IRP2 that are involved in iron homeostasis and 
InsP3R, RyR and SERCA that participate in the regulation of Ca2+ signaling are also 
targeted by ROS. 
Fig. 5. Energy metabolism determines the cell-death pathway of cancer cells. 
Susceptibility of cancer cells to death stimulus is highly dependent on their metabolic 
phenotype. The rapid dismantling and fragmentation of the mitochondrial tubular 
network into small mitochondria (green) occurs as a first response to a death stimulus to 
chemotherapeutic agents. Tumor cells with a significant activity of oxidative 
phosphorylation (OXPHOS) will produce high levels of ROS contributing to the 
oxidation of mitochondrial proteins (red dots) and the release of the mitochondrial 
arsenal involved in the execution of cell death (fragmented nucleus in yellow). Cells 
with a diminished activity of OXPHOS and thus an increased activity of the glycolytic 
pathway will not generate ROS under conventional chemotherapy what results in a 
resistant cell death phenotype.  
Fig. 6. IF1 mediates the oncogenic phenotype by ROS signaling. The illustration 
shows a schematic organization of the mitochondrial H+-ATP synthase. Several 
subunits are color-coded and labeled. In tumor cells, the ATPase Inhibitory Factor 1 
(IF1) (in red) is highly over-expressed and binds the catalytic α /β interface. This 
interaction prevents synthesis of ATP triggering metabolic reprogramming towards an 
enhanced glycolytic phenotype. Inhibition of the H+-ATP synthase also promotes an 
increase in the mitochondrial membrane potencial (Δψm) and the subsequent increase in 
superoxide radical production (ROS).  ROS signaling will activate proliferation and 
survival pathways in the nucleus of the cell. All these events represent hallmarks of 
cancer as they promote tumorigenesis and metastasis.  
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